Loading clinical trials...
Loading clinical trials...
IBSoFACTo : Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics
Severe bacterial infections (SBI) are responsible for significant morbidity and mortality in the paediatric population. There is considerable individual variability in children's susceptibility to developing SBIs. This variability is multifactorial, and the mechanisms at work are not yet fully understood. The investigators of this study therefore propose to study a population of children who had particularly severe bacterial infections requiring hospitalization in a pediatric intensive care unit in France between 2015 and 2018. This study is part of a global approach to understanding the mechanisms favoring the occurrence of IBS in pediatrics. The study will initially focus on analyzing the clinical phenotype of these children in terms of the type of infection presented, as well as immunologically with an immune workup of all these patients. The investigators also plan to contact each family individually to identify other episodes of personal or family IBS or other elements suggestive of immune deficiency (opportunistic infections, autoimmune manifestations, severe atopy). The investigators will also assess the persistent sequelae since their infectious episode, and their quality of life following this IBS. In parallel, the genetic analysis of these patients and their parents will be carried out using whole-exome sequencing. The investigators will compare the results with those obtained in 2 IBS-free control populations (N=70 and N=116). The goal is to identify genetic variants that favor the occurrence of IBS in general, and some that are specific to certain bacteria or clinical presentations.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Nantes University Hospital
Nantes, Loire Atlantique, France
CHU de Brest
Brest, France
Hospices Civils de Lyon
Lyon, France
Hôpital Armand Trousseau
Paris, France
Hôpital Necker enfants malades
Paris, France
CHU de Saint-Étienne
Saint-Etienne, France
Start Date
January 1, 2026
Primary Completion Date
June 1, 2027
Completion Date
June 1, 2029
Last Updated
January 26, 2026
1,401
ESTIMATED participants
Extended phenotyping
OTHER
Blood sample for WES
OTHER
Blood sample for PBMC freezing
OTHER
POPC score evaluation
OTHER
Questionnaire completion
OTHER
Lead Sponsor
Nantes University Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions